Association Testing in 9,000 People Fails to Confirm the Association of the Insulin Receptor Substrate-1 G972R Polymorphism With Type 2 Diabetes
- Jose C. Florez1234,
- Marketa Sjögren5,
- Noël Burtt3,
- Marju Orho-Melander5,
- Steve Schayer3,
- Maria Sun13,
- Peter Almgren5,
- Ulf Lindblad6,
- Tiinamaija Tuomi7,
- Daniel Gaudet8,
- Thomas J. Hudson9,
- Mark J. Daly3,
- Kristin G. Ardlie10,
- Joel N. Hirschhorn31112,
- David Altshuler123411 and
- Leif Groop5
- 1Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts
- 2Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts
- 3Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts
- 4Department of Medicine, Harvard Medical School, Boston, Massachusetts
- 5Department of Endocrinology, University Hospital MAS, Lund University, Malmö, Sweden
- 6Department of Community Medicine, University Hospital MAS, Lund University, Malmö, Sweden
- 7Department of Medicine, Helsinki University Central Hospital; Folkhalsan Genetic Institute, Folkhalsan Research Center; and Research Program for Molecular Medicine, University of Helsinki, Helsinki, Finland
- 8University of Montreal Community Genomic Center, Chicoutimi Hospital, Quebec, Canada
- 9McGill University and Genome Quebec Innovation Centre, Montreal, Canada
- 10Genomics Collaborative, Cambridge, Massachusetts
- 11Department of Genetics, Harvard Medical School, Boston, Massachusetts
- 12Divisions of Genetics and Endocrinology, Children’s Hospital, Boston, Massachusetts
- Address correspondence and reprint requests to David Altshuler, Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114. E-mail: altshuler{at}molbio.mgh.harvard.edu
- Leif Groop, Department of Endocrinology, University Hospital MAS, Lund University, Malmö, Sweden. E-mail: leif.groop{at}endo.mas.lu.se
Abstract
The insulin receptor substrate (IRS)-1 is an important component of the insulin signal transduction cascade. Several reports suggest that a Gly→Arg change in codon 972 is associated with type 2 diabetes and related traits, and a recent meta-analysis reported a modest but nominally significant association with type 2 diabetes (odds ratio [OR] 1.25 in favor of carriers of the Arg allele [95% CI 1.05–1.48). To test the reproducibility of the model in a recent meta-analysis, we examined genotype-phenotype correlation in three large Caucasian samples (not previously reported for this variant) totaling 9,000 individuals (estimated to have >95% power to obtain a P < 0.05 for the OR of 1.25 estimated in the meta-analysis). In our combined sample, comprising 4,279 case and 3,532 control subjects, as well as 1,189 siblings discordant for type 2 diabetes, G972R was not associated with type 2 diabetes (OR 0.96 [0.84–1.10], P = 0.60). Genotype at G972R had no significant effect on various measures of insulin secretion or insulin resistance in a set of Scandinavian samples in whom we had detailed phenotypic data. In contrast, the well-documented associations of peroxisome proliferator-activated receptor γ P12A and Kir6.2 E23K with type 2 diabetes are both robustly observed in these 9,000 subjects, including an additional (previously unpublished) confirmation of Kir6.2 E23K and type 2 diabetes in the Polish and North American samples (combined OR 1.15 [1.05–1.26], P = 0.001). Despite genotyping 9,000 people and >95% power to reproduce the estimated OR from the recent meta-analysis, we were unable to replicate the association of the IRS-1 G972R polymorphism with type 2 diabetes.
- HOMA, homeostasis model assessment
- HOMA-β, HOMA of β-cell function
- HOMA-IR, HOMA of insulin resistance
- IRS, insulin receptor substrate
- ISI, insulin sensitivity index
- OGTT, oral glucose tolerance test
- PI3K, phosphatidylinositol 3-kinase
- PPAR, peroxisome proliferator-activated receptor
Footnotes
-
D.A. and L.G. jointly supervised this project.
In the past, D.A. has been on an advisory panel for and received consulting fees from Genomics Collaborative.
-
- Accepted August 23, 2004.
- Received July 9, 2004.
- DIABETES














